

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shandong Boan Biotechnology Co., Ltd.

山东博安生物技术股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6955)

VOLUNTARY ANNOUNCEMENT

BLA SUBMISSION FOR TWO DENOSUMAB BIOSIMILARS IN THE U.S.

The board of directors (the “**Board**”) of Shandong Boan Biotechnology Co., Ltd. (the “**Company**”) announces that the Company has submitted a Biologics License Application (“**BLA**”) to the U.S. Food and Drug Administration (FDA) for two biosimilars: BA6101 (denosumab injection 60 mg) and BA1102 (denosumab injection 120 mg). This submission marks an important milestone in the Company’s efforts to accelerate the global expansion of its core products.

Denosumab is a RANK ligand (RANKL) inhibitor. BA6101 and BA1102 are biosimilars of the reference products Prolia® and Xgeva®, respectively. The Company’s BLA seeks approval for all indications currently approved for the two reference products: namely, BA6101 for the treatment of conditions related to osteoporosis, and BA1102 for the treatment of conditions related to bone metastases from solid tumors, multiple myeloma, giant cell tumor of bone, and hypercalcemia of malignancy.

BA6101 and BA1102 were independently developed by the Company under its global R&D strategy, following a rigorous, stepwise approach in accordance with relevant biosimilars guidelines of the U.S., the EU, the United Kingdom, Japan, and China. Comprehensive pharmaceutical, non-clinical, human pharmacokinetic, and clinical efficacy studies have confirmed that both products are highly similar to their respective reference products, with no clinically meaningful differences in safety, purity, or efficacy.

With over ten years of clinical use, denosumab is demonstrated to be safe and effective, supported by extensive real-world evidence. It is recommended by multiple authoritative clinical guidelines both in China and internationally. It plays an important role in relevant therapeutic areas and demonstrates significant market potential. Publicly available data shows that in 2025, the combined global sales of Prolia® and Xgeva® were approximately US\$6.498 billion, of which approximately US\$4.333 billion was generated in the U.S.

To accelerate the commercialization of BA6101 and BA1102 in the U.S., the Company entered into an exclusive agreement with a global pharmaceutical company headquartered in China in December 2025 for the nationwide promotion of both products. The partner possesses capabilities spanning across R&D, quality assurance, registration, and sales in the U.S. and it is one of a leading suppliers of injectable therapeutics in the country.

The Company is also actively expanding the global footprint of its denosumab biosimilars beyond the U.S. Both products are commercially available in China, and their Marketing Authorization Applications are under review in the United Kingdom. In addition, BA6101 has obtained marketing approved in Bolivia. The Company will continue to advance the registration and commercialization of both products in the EU, Japan, and other high-potential international markets.

To promote the two denosumab injections globally, the Company has established a robust network of partners across the regions. In China, the Company is partnering with Qingdao Conson Pharmaceutical Co., Ltd. to promote BA6101 in the Chinese Mainland. It is also partnering with Kexing Biopharm Co., Ltd. to commercialize both products in Hong Kong and Macao. Internationally, the Company has partnered with Shanghai Pharmaceutical Co., Ltd. to commercialize the two denosumab injections in certain Southeast Asian countries and with PHARMACARE to commercialize the two denosumab injections in certain Latin America countries.

As the Company's first products to enter international markets, BA6101 and BA1102 are expected to become key growth drivers for the Company's overseas business, and to lay the foundation for the global rollout of its future biologics. Both products are already launched in China and have been well received by both physicians and patients. The Company will continue to work with its partners to strengthen the commercialization of the products and accelerate their launch across key overseas markets. The Company remains committed to improving patient outcomes by delivering high-quality, affordable biologics and improving drug accessibility in relevant therapeutic areas.

By Order of the Board
Shandong Boan Biotechnology Co., Ltd.
Jiang Hua

Chairlady, Chief Executive Officer and Executive Director

Yantai, the People's Republic of China, 29 May 2026

As at the date of this announcement, the executive directors of the Company are Ms. Jiang Hua and Mr. Wang Shenghan; the non-executive directors of the Company are Mr. Liu Yuanhong, Ms. Li Li and Mr. Li Shixu; and the independent non-executive directors of the Company are Professor Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin.